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Mesotherapy is the injection of active substances into the surface layer of the skin. This method allows a slower spread, higher
levels, and longer lasting eﬀects of drugs in the tissues underlying the site of injection (skin, muscle, and joint) compared with
thosefollowingintramuscularinjection.Thistechniqueisusefulwhenalocalpharmacologicaleﬀectisrequiredandrelativelyhigh
doses of drug in the systemic circulation are not. Mesotherapy should only be undertaken following a complete clinical workup
and subsequent diagnosis. Encouraging results have been reported in randomized, controlled clinical trials and in observational
studies involving patients with various forms of musculoskeletal pain. Recommendations by experts from the Italian Society of
Mesotherapyforappropriateuseofmesotherapyinmusculoskeletalpainandanalgorithmfortreatinglocalizedpainfulconditions
are provided.
1.Introduction
Mesotherapy is a technique used to inject active substances
into the superﬁcial layer of the skin [1–4]. The objective
of this type of administration is to modulate the phar-
macokinetics of the injected substance and to prolong the
pharmacological eﬀects at a local level. One of the main
advantages of mesotherapy is that a local pharmacological
eﬀect can be obtained without the need for high systemic
concentrations [4, 5]. Our group has previously demon-
stratedthatintradermalinjectionsofsmallamountsofactive
substance where the injection site corresponds to the area
of the pathological condition—for example, in lower back
pain—may provide clinical beneﬁts where other therapies
are not available/not eﬀective or cannot be used for whatever
reason [5]. In addition, intradermal administration of active
substances in combination with other systemic therapies can
produce synergistic eﬀects, and as a result mesotherapy may
have dose-sparing eﬀects [5].
The correct use of mesotherapy requires clinical and
pharmacological skills. It is vital that the procedure is carried
out using strictly controlled aseptic techniques and that
proper hygiene and sterilization procedures are employed.
As a result of the use of this procedure by nonmedical
personnel, the failure to comply with hygiene standards,
incorrect administration techniques and the misuse of drugs
(medications mixed together), a number of adverse events
havebeenreportedinthemedicalliterature,inparticulardue
to the lack of aseptic conditions [6]. Furthermore, the lack of
randomized clinical trials has raised certain doubts on the
validity of this technique [7, 8]. In this review we present a
criticalanalysisoftheeﬃcacyandtolerabilityofmesotherapy
in patients with painful musculoskeletal conditions.
2. Reasons to Consider Mesotherapy in
Pain Management
Pain is an “unpleasant sensory and emotional experi-
ence associated with actual or potential tissue damage, or
described in terms of such damage” [9]. Acute pain is
interpreted as an alarm signal related to actual or potential2 Evidence-Based Complementary and Alternative Medicine
Table 1: Tissue levels of Na-ketoprofen (μg) detected by chromatography following local intradermal (LIT) or intramuscular (IM)
administration, modiﬁed with permission from [23].
Time (hours)
Skin Muscle Articular tissue
LIT IM LIT IM LIT IM
0 n dn dn dn dn dn d
0.5 124.9 4.8 1.5 33.3 25.8 18.6
1 42.3 t 3 t 19.3 0.3
2 15.6 t 23.8 t 10.8 t
4 10.9 t 19.3 t 8.3 t
7 t nd 100.6 t 6.2 t
10 t nd 102.2 t 7 t
24 nd nd 14.9 nd 0.8 nd
nd = not detectable; t = trace.
tissue damage—when pain persists it can become a serious
condition in its own right [10]. Usually, pain is caused by
stimuli approaching or exceeding harmful intensity, but in
the case of prolonged pain the sensitive feedback system is
altered, and microglia cells are activated [11, 12]. Even if
this hypothesis is not conﬁrmed at clinical level, it could
explain the relationships between the lack of inﬂammatory
substances and the chronic pain and the central nervous
system pain control failure. Chronic pain is deﬁned as pain
that persists for longer than three months [13]. In patients
with arthritis or other musculoskeletal conditions, pain is
frequently triggered by inﬂammation of peripheral tissues
(nociceptive pain), but it is also associated with a lesion (or
dysfunction)ofthenervepathways(neuropathicpain).More
often, nociceptive pain and neuropathic pain coexist partic-
ularlyinpatientswithchronicbackpain[14].Unfortunately,
there is no universally recognised standard of care as there is
a number of distinct pathological mechanisms of pain (acute
or chronic) as well as a wide range of therapeutic options
to manage patients with chronic pain including pharmaco-
logicalandinterventionaltreatmentsphysical,psychological,
complementary and alternative medicine approaches [15].
In Europe nonsteroidal anti-inﬂammatory drugs (NSAIDs)
are the ﬁrst-line therapy in the majority of patients with
musculoskeletal pain in conjunction with nonpharmacolog-
ical therapies, such as exercise, physiotherapy, acupuncture
and herbal-based preparations [16]. The high frequency of
adverse events with NSAIDs—gastrointestinal toxicity, renal
dysfunction, cardiovascular complications, and the risk of
drug–drug interactions, particularly in older patients with
comorbidities—in part explains the increasingly widespread
use of “alternative” treatments [17]. Local pharmacological
therapy, if eﬀective and well tolerated, represents an accept-
able alternative to systemic NSAIDs [18, 19].
Mesotherapy consists of a series of “microinjections” of
drug/active substance into the dermis using short needles
where the needle is positioned at an appropriate angle
depending on the thickness of the skin. We suggest using
a single needle, 4mm (27 gauge) or 13mm (30 or 32
gauge), positioned at 30–45 degree with respect to the
skin surface. In general, 0.10–0.20mL of product is used
and injection points are usually 2 or 3cm apart. If large
areas are to be treated, the drug can be diluted, but this
reduces the dosage, and, therefore, additional or more
frequent injections are necessary. Following injection, the
drug slowly reaches the underlying tissues achieving con-
centrations higher than those obtained with intramuscular
administration [5]. Interestingly, some authors consider
mesotherapy as an intra- or subcutaneous technique; how-
ever, subcutaneously administered drugs may have diﬀerent
pharmacokinetics(diﬀusionanddistribution)andasaresult
diﬀerent onset and duration of activity depending on the
site of injection [20, 21]. For example, plasma glucose levels
vary depending on the subcutaneous site of injection—
abdomen, arm, or leg—due to the level of absorption at
the various injection sites [22]. In contrast, injection into
the superﬁcial layer of the skin (intradermal) allows slow
diﬀusion of the drug into the tissues underlying the site of
injection. Sodium ketoprofen levels in skin, muscles, and
joints following local intradermal or intramuscular (IM)
have been measured in preclinical studies, and results show
higher concentrations of the drug in skin, local muscles,
and joints (corresponding the site of injection) following
intradermal administration compared with following IM
injection and these levels which remain high for longer than
following IM administration (Table 1)[ 5, 23]. These results
wereconﬁrmedwiththeintradermalinoculationofprocaine
and penicillin G [24, 25]. Similar results were demonstrated
in human studies following intradermal injection (up to
4mm), and interestingly results conﬁrmed that when a drug
is injected at a depth of more than 10mm it remains for
a short time in the surrounding tissues and reaches the
systemic circulation rapidly [6].
To conﬁrm that LIT administration provides prolonged
concentrationofdrugstolocaltissues,astudywasconducted
to compare the immunogenic properties of the tetanus
toxoid after intradermal and IM administration [26]. This
preclinical study showed that more potent immunologi-
cal responses (primary and secondary) were elicited after
intradermal injection. The authors suggest that the unique
capacity of dermis to respond to external stimuli together
with the increased distribution of antigen at the area ofEvidence-Based Complementary and Alternative Medicine 3
inoculation may go some way to explain these ﬁndings
and have shown the way to a renewed interest in using
intradermal administration of human vaccines to reduce
antigen concentration (dose sparing) and the possibility of
reducing the need for adjuvants (drug sparing) [27].
A recently published study reported that the adminis-
tration of recombinant human follicle-stimulating hormone
(rhFSH) injected into the abdominal skin at a depth of 1-
2mm, instead of using subcutaneous (10–13mm) adminis-
tration, extended the absorption of FSH. These data conﬁrm
the many potential clinical advantages of using intradermal
injection—dose reduction, reduced number of injections
needed to maintain elevated FSH levels, and reduced risk of
adverse events [28]. The superﬁcial layer of the skin appears
to suggest a sort of an innate “slow-release system” (to be
demonstrated with other preclinical and clinical studies),
and it is interesting to note that the terminology “local
intradermal therapy” is used to highlight the fact that it
modulates the absorption and diﬀusion of drugs at a local
level [5], even if till today studies were not produced with the
technique of microdialysis.
However, the pharmacological eﬀects of intradermal
administration do not account entirely for the observed
clinical beneﬁts of mesotherapy. It is thought that “micro-
doses” of active substances produce a mechanical distention
of the surrounding tissues and sensitive ﬁbres. The needle
prick activates the cutaneous and subcutaneous receptors
(reﬂex eﬀect), and it is thought that endorphins levels
actually increase after the introduction of the needle, but this
hypothesis was not conﬁrmed. Furthermore, interactions
between the microvascular system and the immune cells in
the dermis may play a role in the clinical beneﬁts [29, 30].
Finally, we can argue that the clinical beneﬁts reported by
patientstreatedwithanalgesicdrugsbyintradermalinjection
may be the result of a series of “mesodermic phenomena”
that are commonly referred to as mesotherapy.
3. ClinicalTrials of Mesotherapy in
MusculoskeletalPain
The ﬁrst series of open studies conducted in patients
with musculoskeletal pain conditions—including arthritis,
neck pain, lower back pain, and tendinopathy—showed
promising results in termss of pain reduction of at least
50% compared to baseline (Table 2)[ 31–46]. Positive results
in term of reduction of pain and complete recovery were
also reported in clinical studies conducted in professional
and amateur athletes with posttraumatic pain (Table 3)
[47–52]. In randomized and controlled trials, clinical
beneﬁts were reported in patients with low back pain,
with cervicobrachialgia, and with calcifying tendinitis of
the shoulder (Table 4)[ 53–57]. Conﬁrming those previ-
ously reported by other authors showing pain relief and
reduction of calciﬁcation [39, 43, 58, 59]. Interestingly,
better results were reported when mesotherapy was com-
bined with other therapies, for example, transcutaneous
electric nerve stimulation (TENS) and laser or dynamic
therapy [45, 54, 60–62]. Preliminary positive data have
also been obtained in painful orodental conditions [63–
65].
4.AdverseEventsandLocalReactions
to Mesotherapy
Whilethereisagreatdealofdatashowingthatthistechnique
is well tolerated (Tables 2–4), transitory and reversible
adverse reactions (allergic reactions, ecchymosis, and urtica)
have been described after mesotherapy [4]. Mesotherapy can
cause mild discomfort when the needle is introduced, and
thisismorecommoninsensitivepatients.Forthisreasonitis
recommendedthattheneedleshouldbeinsertedquicklyand
gentlyandthatthecontentsofthesyringeareemptiedslowly.
The diﬀerent pH of some medications can cause pain during
injection, and adjustment of pH with NaHCO3 has been
suggested [66]. However, it is not clear if the painful stimulus
caused by microinjections represents an artiﬁcial painful
impulse (pain scrambler) that participates in the interrup-
tionoftransmissionof“pain”[67–69].Otherlocaltransitory
eﬀects (itching, hypersensitivity, discomfort, and irritation),
probably due to the type of drug [70] or combination of
drugs [38], have been reported. The use of a single drug
appearstoreducetheriskofdrug-druginteractionsandlocal
side eﬀects, and the risk of infection is avoided if correct
ascetic procedures are employed [5]. Literature reports that
the subcutaneous infections [6, 71] seem to be caused by
external contamination and malpractice rather than to the
technique itself.
5. Role of Skin Cytochromes
The potential role of skin cytochromes is still under dis-
cussion both for the pathway of drugs and local interac-
tion [72–77]. The cytochromes expressed in human ker-
atocytes could inﬂuence a number of active compounds
available for transdermal administration (analgesics, anti-
inﬂammatories, antibiotics, antifungal, and a large number
of products recommended by manufacturers for their anti-
aging eﬀects), but there are very little data available on pos-
sible drug-drug interactions, metabolic pathway activation,
photosensitivity reactions, or other bioactivities [78, 79]. For
this reason it is preferable to avoid pharmacological mixtures
of drugs, drug combined with herbal medicines or other
active substances injected by intradermal route.
6. Rationalefor Analgesic DrugsInjectedat
LocalLevel
A large percentage of patients treated with mesotherapy
for musculoskeletal pain disorders had rapid pain relief,
generally when the patient responds within the ﬁrst three
sessions of therapy [31–57, 60]. Importantly, in all the
studies reviewed in which a wide range of agents (NSAIDs,
myorelaxants, EDTA, calcitonin, or vasorelaxants alone or
in combination with an anesthetic) were injected at a local
level using mesotherapy, no signiﬁcant adverse events were4 Evidence-Based Complementary and Alternative Medicine
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2
]
D
e
g
e
n
e
r
a
t
i
v
e
a
r
t
h
r
o
s
i
s
i
n
a
n
e
w
a
c
u
t
e
s
t
a
g
e
o
f
p
a
i
n
9
6
P
O
N
S
A
I
D
s
,
s
-
a
d
e
n
o
s
i
l
l
-
m
e
t
h
i
o
n
i
n
e
,
a
n
d
p
r
o
c
a
i
n
e
N
C
1
y
e
a
r
6
s
e
s
s
i
o
n
s
f
o
r
1
,
2
,
o
r
3
c
y
c
l
e
i
n
a
y
e
a
r
R
e
d
u
c
t
i
o
n
o
f
p
a
i
n
,
d
r
u
g
s
c
o
n
s
u
m
p
t
i
o
n
(
6
7
%
)
,
a
n
d
a
b
s
e
n
c
e
s
f
r
o
m
w
o
r
k
(
3
0
%
)
B
i
o
n
d
i
e
t
a
l
.
1
9
8
5
[
4
3
]
T
e
n
d
i
n
i
t
i
s
,
s
c
a
p
u
l
o
h
u
m
e
r
a
l
p
e
r
i
a
r
t
h
r
i
t
i
s
4
4
P
C
S
u
p
e
r
o
x
i
d
e
d
i
s
m
u
t
a
s
e
(
S
O
D
)
a
n
d
m
e
p
i
v
a
c
a
i
n
e
M
e
p
i
v
a
c
a
i
n
e
5
m
o
n
t
h
s
3
–
6
s
e
s
s
i
o
n
s
e
v
e
r
y
4
–
8
d
a
y
s
P
a
i
n
r
e
d
u
c
t
i
o
n
i
n
9
0
%
o
f
p
t
s
o
r
r
e
c
o
v
e
r
y
i
n
t
h
e
S
O
D
+
a
n
e
s
t
h
e
t
i
c
g
r
o
u
p
v
e
r
s
u
s
3
3
%
i
n
t
h
e
g
r
o
u
p
w
i
t
h
t
h
e
a
n
e
s
t
h
e
t
i
c
a
l
o
n
e
P
e
z
o
n
e
e
t
a
l
.
1
9
8
6
[
4
4
]
O
s
t
e
o
p
o
r
o
s
i
s
/
a
r
t
h
r
i
t
i
s
3
2
P
O
C
a
l
c
i
t
o
n
i
n
e
N
C
2
–
1
0
w
e
e
k
s
w
e
e
k
l
e
y
s
e
s
s
i
o
n
s
P
a
i
n
r
e
d
u
c
t
i
o
n
(
7
6
.
5
%
o
f
p
t
s
)
i
n
p
a
r
t
i
c
u
l
a
r
i
n
p
t
s
w
i
t
h
o
s
t
e
o
p
o
r
o
s
i
s
a
n
d
a
r
t
h
r
i
t
i
s
S
o
l
i
n
a
s
e
t
a
l
.
1
9
8
7
[
4
5
]
T
e
n
d
i
n
o
p
a
t
h
i
e
s
2
0
P
O
E
r
g
o
t
e
i
n
e
N
C
n
r
n
r
C
o
m
b
i
n
a
t
i
o
n
w
i
t
h
l
a
s
e
r
t
h
e
r
a
p
y
m
o
r
e
e
ﬀ
e
c
t
i
v
e
(
i
n
t
e
r
m
o
f
p
a
i
n
r
e
d
u
c
t
i
o
n
)
t
h
a
n
t
r
a
d
i
t
i
o
n
a
l
t
h
e
r
a
p
i
e
s
G
a
r
z
y
a
e
t
a
l
.
1
9
8
7
[
4
6
]
M
u
s
c
u
l
a
r
s
k
e
l
e
t
a
l
p
a
i
n
1
0
0
P
O
C
N
S
A
I
D
s
a
n
d
a
n
e
s
t
h
e
t
i
c
N
a
p
r
o
x
e
n
,
l
y
s
i
n
e
a
c
e
t
y
l
s
a
l
i
c
y
l
a
t
e
,
a
n
d
k
e
t
o
p
r
o
f
e
n
5
2
d
a
y
s
3
s
e
s
s
i
o
n
a
t
w
e
e
k
l
e
y
i
n
t
e
r
v
a
l
s
P
a
i
n
r
e
d
u
c
t
i
o
n
;
n
o
d
i
ﬀ
e
r
e
n
c
e
s
b
e
t
w
e
e
n
N
S
A
I
D
s
e
v
a
l
u
a
t
e
d
.
P
t
s
w
i
t
h
c
e
r
v
i
c
o
d
y
n
i
a
a
n
d
g
o
n
a
l
g
i
a
r
e
c
e
i
v
e
d
b
e
t
t
e
r
c
l
i
n
i
c
a
l
b
e
n
e
ﬁ
t
s
T
h
e
t
a
b
l
e
l
i
s
t
s
c
l
i
n
i
c
a
l
s
t
u
d
i
e
s
o
r
c
a
s
e
r
e
p
o
r
t
s
t
o
e
v
a
l
u
a
t
e
t
h
e
r
e
d
u
c
t
i
o
n
o
f
p
a
i
n
i
n
v
a
r
i
o
u
s
c
l
i
n
i
c
a
l
c
o
n
d
i
t
i
o
n
s
.
T
h
e
p
a
i
n
w
a
s
n
o
t
e
d
w
i
t
h
v
i
s
u
a
l
s
c
a
l
e
s
.
M
:
m
u
l
t
i
c
e
n
t
r
i
c
,
R
:
r
e
t
r
o
s
p
e
c
t
i
v
e
,
P
:
p
r
o
s
p
e
c
t
i
v
e
,
O
:
o
p
e
n
,
C
:
c
o
n
t
r
o
l
l
e
d
,
N
C
:
n
o
n
c
o
n
t
r
o
l
l
e
d
,
C
S
:
c
a
s
e
r
e
p
o
r
t
,
a
n
d
n
r
:
n
o
n
r
e
p
o
r
t
e
d
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T
a
b
l
e
3
:
C
l
i
n
i
c
a
l
s
t
u
d
i
e
s
c
o
n
d
u
c
t
e
d
i
n
a
t
h
l
e
t
e
s
b
o
t
h
p
r
o
f
e
s
s
i
o
n
a
l
a
n
d
a
m
a
t
o
r
y
w
i
t
h
p
o
s
t
t
r
a
u
m
a
t
i
c
p
a
i
n
.
S
t
u
d
y
D
i
s
e
a
s
e
N
o
.
o
f
p
a
t
i
e
n
t
s
S
t
u
d
y
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
D
r
u
g
s
u
t
i
l
i
z
e
d
C
o
n
t
r
o
l
P
e
r
i
o
d
o
f
f
o
l
l
o
w
u
p
N
o
.
o
f
s
e
s
s
i
o
n
s
O
u
t
c
o
m
e
C
e
r
e
s
e
r
e
t
a
l
.
1
9
8
5
[
4
7
]
P
a
i
n
p
o
s
t
t
r
a
u
m
a
t
i
c
i
n
r
u
g
b
y
p
r
o
f
e
s
s
i
o
n
a
l
p
l
a
y
e
r
s
1
3
3
R
O
N
S
A
I
D
s
,
m
y
o
r
e
l
a
x
a
n
t
,
v
a
s
o
r
e
l
a
x
a
n
t
,
a
n
d
m
e
p
i
v
a
c
a
i
n
e
N
C
u
p
t
o
4
m
o
n
t
h
s
1
–
4
s
e
s
s
i
o
n
s
P
a
i
n
r
e
d
u
c
t
i
o
n
a
n
d
f
u
n
c
t
i
o
n
a
l
r
e
c
o
v
e
r
i
n
g
o
f
s
p
o
r
t
i
n
g
c
o
m
p
e
t
i
t
i
v
e
a
c
t
i
v
i
t
y
i
n
s
h
o
r
t
e
r
t
i
m
e
t
h
e
n
c
o
n
v
e
n
t
i
o
n
a
l
t
h
e
r
a
p
i
e
s
G
r
i
b
a
u
d
o
e
t
a
l
.
1
9
8
2
[
4
8
]
P
u
b
i
c
m
y
o
e
n
t
h
e
s
i
t
i
s
2
5
6
P
O
N
S
A
I
D
s
a
n
d
v
a
s
o
r
e
l
a
x
a
n
t
N
C
6
m
o
n
t
h
s
f
r
o
m
2
t
o
5
s
e
s
s
i
o
n
s
a
t
1
0
–
2
0
-
d
a
y
i
n
t
e
r
v
a
l
s
C
o
m
p
l
e
t
e
f
u
n
c
t
i
o
n
a
l
r
e
c
o
v
e
r
y
a
f
t
e
r
4
s
e
s
s
i
o
n
s
L
e
p
o
r
e
a
n
d
S
a
v
i
n
o
1
9
8
3
[
4
9
]
A
c
u
t
e
l
u
m
b
o
s
c
i
a
t
i
c
p
a
i
n
i
n
a
t
h
l
e
t
e
s
2
0
P
O
N
e
u
r
a
m
i
d
i
u
m
,
P
r
o
c
a
i
n
e
N
C
4
m
o
n
t
h
s
2
–
6
s
e
s
s
i
o
n
s
P
a
i
n
r
e
d
u
c
t
i
o
n
a
n
d
f
u
n
c
t
i
o
n
a
l
r
e
c
o
v
e
r
y
i
n
9
0
%
o
f
p
t
s
G
r
i
b
a
u
d
o
e
t
a
l
.
1
9
8
6
[
5
0
]
P
a
t
e
l
l
a
r
t
e
n
d
o
n
i
t
i
s
1
2
6
P
O
S
u
p
e
r
o
x
i
d
e
d
i
s
m
u
t
a
s
e
(
S
O
D
)
,
l
i
d
o
c
a
i
n
e
,
a
n
d
v
a
s
o
r
e
l
a
x
a
n
t
N
C
1
m
o
n
t
h
w
e
e
k
l
e
y
s
e
s
s
i
o
n
s
8
5
%
o
f
p
t
s
r
e
a
c
h
c
o
m
p
l
e
t
e
p
a
i
n
r
e
l
i
e
f
(
f
o
r
m
1
t
o
4
s
e
s
s
i
o
n
s
)
G
r
i
b
a
u
d
o
e
t
a
l
.
1
9
8
6
[
5
1
]
I
l
e
o
-
t
i
b
i
a
l
b
a
n
d
f
r
i
c
t
i
o
n
s
y
n
d
r
o
m
e
4
0
P
O
N
S
A
I
D
S
,
v
a
s
o
r
e
l
a
x
a
n
t
,
a
n
d
a
n
e
s
t
h
e
t
i
c
N
C
3
m
o
n
t
h
s
w
e
e
k
l
y
s
e
s
s
i
o
n
s
P
a
i
n
r
e
l
i
e
f
i
n
5
5
%
o
f
p
t
s
a
f
t
e
r
2
s
e
s
s
i
o
n
s
;
9
7
.
5
%
a
f
t
e
r
3
s
e
s
s
i
o
n
s
G
r
i
b
a
u
d
o
e
t
a
l
.
1
9
8
7
[
5
2
]
M
y
o
n
t
h
e
s
i
t
i
s
o
f
t
h
e
l
e
g
2
0
3
P
O
N
S
A
I
D
s
,
v
a
s
o
r
e
l
a
x
a
n
t
,
a
n
d
l
i
d
o
c
a
i
n
e
N
C
2
m
o
n
t
h
s
s
e
s
s
i
o
n
s
a
t
7
-
8
-
d
a
y
i
n
t
e
r
v
a
l
s
6
0
.
8
%
o
f
p
t
s
r
e
a
c
h
c
o
m
p
l
e
t
e
r
e
c
o
v
e
r
y
w
i
t
h
1
s
e
s
s
i
o
n
;
9
6
.
6
%
o
f
p
t
s
r
e
a
c
h
c
o
m
p
l
e
t
e
r
e
c
o
v
e
r
y
w
i
t
h
3
s
e
s
s
i
o
n
s
.
M
e
s
o
t
h
e
r
a
p
y
w
a
s
m
o
r
e
e
ﬃ
c
a
c
y
i
n
p
t
s
w
i
t
h
r
e
c
e
n
t
p
a
i
n
.
T
h
e
t
a
b
l
e
l
i
s
t
s
c
l
i
n
i
c
a
l
s
t
u
d
i
e
s
t
o
e
v
a
l
u
a
t
e
t
h
e
r
e
d
u
c
t
i
o
n
o
f
p
a
i
n
i
n
v
a
r
i
o
u
s
c
l
i
n
i
c
a
l
c
o
n
d
i
t
i
o
n
s
.
T
h
e
p
a
i
n
w
a
s
n
o
t
e
d
w
i
t
h
v
i
s
u
a
l
s
c
a
l
e
s
.
R
:
r
e
t
r
o
s
p
e
c
t
i
v
e
,
P
:
P
r
o
s
p
e
c
t
i
v
e
,
O
:
o
p
e
n
,
a
n
d
N
C
:
n
o
n
c
o
n
t
r
o
l
l
e
d
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T
a
b
l
e
4
:
R
a
n
d
o
m
i
z
e
d
,
c
o
n
t
r
o
l
l
e
d
c
l
i
n
i
c
a
l
t
r
i
a
l
i
n
p
a
t
i
e
n
t
s
w
i
t
h
l
o
w
b
a
c
k
p
a
i
n
,
c
e
r
v
i
c
o
b
r
a
c
h
i
a
l
g
i
a
a
n
d
c
a
l
c
i
ﬁ
c
p
a
i
n
f
u
l
t
e
n
d
i
n
i
t
i
s
o
f
t
h
e
s
h
o
u
l
d
e
r
.
S
t
u
d
y
D
i
s
e
a
s
e
N
o
.
o
f
p
a
t
i
e
n
t
s
S
t
u
d
y
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
D
r
u
g
s
u
t
i
l
i
z
e
d
C
o
n
t
r
o
l
P
e
r
i
o
d
o
f
f
o
l
l
o
w
u
p
N
o
.
o
f
s
e
s
s
i
o
n
s
O
u
t
c
o
m
e
P
a
r
r
i
n
i
e
t
a
l
.
2
0
0
2
[
5
3
]
A
c
u
t
e
l
u
m
b
o
s
c
i
a
t
i
c
p
a
i
n
s
y
n
d
r
o
m
e
4
4
R
A
A
c
e
t
y
l
s
a
l
i
c
y
l
i
c
a
c
i
d
P
C
1
d
a
y
1
P
a
i
n
r
e
d
u
c
t
i
o
n
/
s
a
f
e
t
y
M
o
n
t
i
c
o
n
e
e
t
a
l
.
2
0
0
4
[
5
4
]
L
o
w
b
a
c
k
p
a
i
n
(
s
a
c
r
o
i
l
i
a
c
d
y
s
f
u
n
c
t
i
o
n
)
2
2
R
A
P
C
N
S
A
I
D
s
L
a
s
e
r
t
h
e
r
a
p
y
1
y
e
a
r
2
s
e
s
s
i
o
n
p
e
r
w
e
e
k
(
8
s
e
s
s
i
o
n
s
)
P
a
i
n
r
e
d
u
c
t
i
o
n
b
e
t
t
e
r
f
o
r
m
e
s
o
t
h
e
r
a
p
y
,
e
x
e
r
c
i
s
e
a
n
d
d
y
n
a
m
i
c
s
u
p
p
o
r
t
t
h
a
n
l
a
s
e
r
t
h
e
r
a
p
y
C
o
s
t
a
n
t
i
n
o
e
t
a
l
.
2
0
1
0
[
5
5
]
L
o
w
b
a
c
k
p
a
i
n
8
4
R
A
P
C
L
i
d
o
c
a
i
n
e
,
k
e
t
o
p
r
o
f
e
n
,
a
n
d
m
e
t
h
y
l
p
r
e
d
n
i
s
o
l
o
n
e
S
t
a
n
d
a
r
d
t
h
e
r
a
p
y
k
e
t
o
p
r
o
f
e
n
,
e
s
o
m
e
p
r
a
z
o
l
e
a
n
d
m
e
t
h
y
l
p
r
e
d
n
i
s
o
l
o
n
e
6
m
o
n
t
h
s
5
s
e
s
s
i
o
n
s
S
a
m
e
e
ﬃ
c
a
c
y
a
n
d
s
a
f
e
t
y
s
y
s
t
e
m
i
c
t
h
e
r
a
p
y
D
i
C
e
s
a
r
e
e
t
a
l
.
2
0
1
0
[
5
6
]
L
o
w
b
a
c
k
p
a
i
n
6
2
R
A
P
C
L
i
d
o
c
a
i
n
e
M
e
s
o
t
h
e
r
a
p
y
i
n
a
c
u
p
u
n
c
t
u
r
e
p
o
i
n
t
s
v
e
r
s
u
s
m
e
s
o
t
h
e
r
a
p
y
i
n
t
r
i
g
g
e
r
p
o
i
n
t
s
1
2
w
e
e
k
s
4
s
e
s
s
i
o
n
s
B
e
t
t
e
r
r
e
d
u
c
t
i
o
n
o
f
p
a
i
n
w
i
t
h
m
e
s
o
t
h
e
r
a
p
y
i
n
a
c
o
p
u
n
t
u
r
e
p
o
i
n
t
s
C
a
c
c
h
i
o
e
t
a
l
.
2
0
0
9
[
5
7
]
C
a
l
c
i
ﬁ
c
t
e
n
d
i
n
i
t
i
s
o
f
t
h
e
s
h
o
u
l
d
e
r
8
0
R
A
D
B
D
i
s
o
d
i
u
m
E
D
T
A
a
n
d
p
r
o
c
a
i
n
e
P
C
1
y
e
a
r
1
s
e
s
s
i
o
n
a
t
w
e
e
k
l
y
i
n
t
e
r
v
a
l
s
f
o
r
3
w
e
e
k
s
C
a
l
c
i
ﬁ
c
a
t
i
o
n
d
i
s
a
p
p
e
a
r
e
d
c
o
m
p
l
e
t
e
l
y
i
n
6
2
.
5
%
a
n
d
p
a
r
t
i
a
l
l
y
i
n
2
2
.
5
%
o
f
p
t
s
;
p
a
r
t
i
a
l
l
y
e
ﬀ
e
c
t
s
w
e
r
e
r
e
g
i
s
t
e
r
e
d
i
n
1
5
%
o
f
p
t
s
i
n
t
h
e
c
o
n
t
r
o
l
g
r
o
u
p
P
a
l
e
r
m
o
e
t
a
l
.
1
9
9
1
[
6
0
]
C
e
r
v
i
c
o
b
r
a
c
h
i
a
l
g
i
a
2
0
R
A
P
O
C
L
i
d
o
c
a
i
n
e
a
n
d
m
y
o
r
e
l
a
x
a
n
t
T
E
N
S
2
0
d
a
y
s
6
T
E
N
S
4
m
e
s
o
t
h
e
r
a
p
y
M
e
s
o
t
h
e
r
a
p
y
c
o
m
b
i
n
e
d
w
i
t
h
T
E
N
S
i
m
p
r
o
v
e
s
s
y
m
p
t
o
m
s
m
a
n
a
g
e
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observed. In these studies a low dose of NSAIDs was
frequently used.
The World Health Organization (WHO) since 1986
recommends a therapeutic approach for the management of
pain based on a three-step process according to the severity
of the pain with NSAIDs used in the ﬁrst step [80].
These drugs exhibit analgesic eﬀects by COX inhibition
and the reduction of prostaglandin and other inﬂammatory
mediators [81]. Nitric oxide seems to play a major part
in local inﬂammation [82], and the injection of analgesic
drugs(includingNSAIDs)mayactivateneuronalnitricoxide
synthase to produce nitric oxide and consequently periph-
eral antinociception [83]. NSAIDs are useful in a broad
range of painful conditions, but renal and gastrointestinal
toxicity and cardiovascular complications that occur during
the long-term systemic administration constitute a major
limitation fortheiruse in patients with chronic pain [84,85].
Administration of NSAIDs by intradermal injection could
represent an alternative therapeutic strategy as lower doses
and reduced frequency of administration compared with
systemic administration required to obtain the same level
of pain control [55]. The drug-sparing beneﬁts of NSAIDs
administered by mesotherapy, alone or in combination with
other systemic therapies, remain to be quantiﬁed. Some
authors report that NSAIDs are safe in combination with
other agents [55], and several trials investigated NSAIDs and
anestheticsgivenincombination,butitisimportanttostress
that if changes in pH, colour, precipitation, or ﬂocculation
are observed it is preferable to avoid the use of the “cocktails”
of drugs. In addition, if skin or systemic reactions occur it is
not possible to establish which drug is responsible.
In myofascial syndrome where pain is caused by muscle
spasm and hyperactivity of muscle ﬁbers, myorelaxants seem
to be a rational choice [31–33, 35, 38, 47]. Mechanical,
chemical, or heat stimuli in the skin, muscles, and joints are
translated into action potential by primary sensory neurons
which constitute Aδ and c-ﬁbers. These primary neurons
upregulate opioid receptor expression, and nerve growth
factors are released into the peripheral tissues during the
inﬂammatory process. It might be that opioids have a role
in pain control during the inﬂammatory process, and the
fact that local administration of opioid-receptors antagonists
may exacerbate pain support this thesis [86]. Although
morphine is normally given subcutaneously, no clinical
data are available when morphine is given intradermally.
The intradermal route of administration of morphine is an
exciting area to study as it may allow a lower dose to be
administered while providing eﬀective pain control.
It still remains to be clariﬁed if the site of injection
plays a role. The eﬀects of trigger-point mesotherapy and
acupuncture-point mesotherapy (both with lidocaine) were
recently compared [56], but large clinical trials are required
to better understand the musculoskeletal mechanisms of
pain before one method over another can be recommended.
Pain relief achieved by myofascial trigger-point injections
of bupivacaine was reversed with intravenous naloxone
[87], providing clear evidence that the endogenous opioid
system is involved in pain reduction at the level of some
trigger points and that opioids play a role in the activation
of peripheral mechanisms of nociception. It has also been
s u g g e s t e dt h a tk e r a t i n o c y t e sa sw e l la sTl y m p h o c y t e sa r e
involved in peripheral nociception, but the therapeutic
implications of these activities remain to be established
[88, 89].
7. Recommendations
In 2010, a panel of experts from a range of specialities
reviewed and validated the scientiﬁc rationale, advantages,
indications and contraindications of the use of mesotherapy,
with the aim of formulating a series of recommendations on
the appropriate use of local intradermal therapy [5]. There
was overwhelming consensus among the group members
that local intradermal administration is a valuable thera-
peutic option in the treatment of painful and locoregional
conditions, and if used correctly it represents an important
addition to the physicians’ armamentarium [5]. The experts
agreed that mesotherapy should be performed only after a
medical diagnosis, and patients should receive information
on risk/beneﬁts ratio in particular when oﬀ-label drugs are
used. They also recommended strongly that the patient’s
written informed consent should always be obtained before
the procedure is carried out to ensure that all possible
therapeutic options have been explored and considered. A
complete patient clinical report form to include a detailed
report of the characteristics of the patient’s condition and
pharmacological (drugs, doses, and route of administration)
andnonpharmacologictechniquespreviously/currentlyused
together with outcome reports and details of any adverse
events observed/reported is mandatory. In this way system-
atic data can be collected and analyzed retrospectively to
determine the eﬃcacy of a given therapeutic approach, and
clinicaldatacanbesharedamongthemultidisciplinaryteam.
This procedure has been adopted in Italy since March 2010
where physicians and other healthcare personnel involved
have an obligation to record all information in the patient’s
clinical record. The use of previously untested compounds
should be avoided (the exception being clinical trials that
conform to good clinical practice, with ethical committee
agreement). The physician should supply patients with
information in a clear way so that he/she can make an
informed decision. All adverse events should be reported to
the pharmacovigilance health authorities.
The use of a mixture of drugs did not receive full
consensus among experts due to the increased risk of
pharmacological interactions, even if in some circumstances
twoactiveingredientshavebeenreportedtobesafe(thereare
no data on possible drug interactions, although changes in
pH, color, and precipitation/ﬂocculation have been observed
in mixtures of drugs. Moreover, using drug mixtures, it is
not possible to identify the eﬀects of individual drugs both
in terms of eﬃcacy and tolerability). Particular attention
should be paid to conforming to international hygiene
standards and to avoid contamination of the sterile syringes
and needles. Before using intradermal therapy, or other
therapies, an internationally validated scale should be used
to classify pain based on the type and intensity. MesotherapyEvidence-Based Complementary and Alternative Medicine 9
Mesotherapy, (ITD)
algorithm of treatment
Clinical evaluation, pharmacologic history
Weekly sessions
for 4 weeks
NRS reduction
>70%
NRS <3 NRS <3
NRS reduction
<50%
NRS 5–7 NRS 8–10
Session at 15-day intervals as needed
Sessions at 15-
day interval
until NRS
reduction of
>70%
Monthly sessions as needed
Weekly sessions
for 4 weeks
NRS reduction
70%
Weekly sessions
until pain
reduction NRS of
50%
Sessions at 15-
day interval as
needed
NRS <5
NRS <50%
NRS >8
Weekly sessions
until NRS
reduction of >
50%
Weekly sessions
until pain
reduction NRS of
50%
Sessions at 3-day
interval until a
reduction of pain
NRS of 50%
ITD with NSAIDs myorelaxant ITD with NSAIDs myorelaxant
If pain persists,
consider a new
clinical evaluation
and a global
therapy
assessment
Session at 15-
day intervals
as needed
Weekly sessions
until NRS
reduction of >
50%
NRS 1–4
NRS >70%
NRS >5
If high doses of analgesics cannot be administered NSAIDs or the therapy is not able to reach pain
control for musculoskeletal pain
Figure 1: Example of algorithm for the use of NSAIDs and myorelaxant with mesotherapy (intradermal therapy—ITD) in musculoskeletal
pain.
is recommended in the management of musculoskeletal
pain alone or in combination with other therapies where
there are no contraindications to the pharmacologically
active agents. Mesotherapy is not recommended in patients
with a history of allergic reactions, disorders of coagulation
(haemophiliacs, undergoing therapy with anticoagulants or
antiplatelet agents), pregnant or lactating women, or cancer
patients undergoing chemotherapy. Due to the broad range
of pain mechanisms and the lack of a recognized standard of
care, when mesotherapy is used the patient’s response drives
subsequent clinical decisions, and the number of sessions
depends on the severity of the pain. Mesotherapy protocols
allow for one or more cycles of treatment depending on
the symptoms and severity of the underlying condition
and the individual patient’s response to therapy (Figure 1).
Whentreatingachronicpainfulconditiontherearenormally
three distinct phases. The ﬁrst period (attack) to reduce
pain, a second (control) period to conﬁrm the results
and to improve eﬃcacy/tolerability ratio, and a subsequent
(maintenance) period to prevent recurrences [4]. In real-
life clinical practice, we propose an example of algorithm
to manage patients who can beneﬁt from a local treat-
ment instead of a systemic more aggressive pharmacologic
approach or who can beneﬁt from a synergistic combination
oflocalandsystemictherapy.Obviously,everyphysicianwho
applies mesotherapy for analgesic purposes should assess
pain before and during the treatment. For this reason we
strongly suggest the use of validated scales to assess pain and
to consider extending the mesotherapy treatment only if the
patient declares a relief of at least 50% from baseline.
8. Conclusions
For many years, mesotherapy has been considered by
physicians (and nonmedical personnel) as a “personal”
pharmacological approach, treatment practices were based
on personal observations and experience, but in the era
of evidence-based medicine this approach is no longer
adequate, and standard treatment algorithms are required.
We have reviewed and analyzed the data available in the
treatment of various forms of musculoskeletal pain, and
although the number of randomized, controlled trials is
still low, overall results suggest that this technique provides
clinical beneﬁts and importantly is well tolerated. Mesother-
apy allows the drug to diﬀuse slowly into the tissues at the
site of injection and to have a prolonged period of action
at low dosages. Microinjections facilitate the rebalancing of
the nociceptive system through a series of complex and as
yet not well-understood local actions involving nociceptive
receptors, nociceptive central feedback mechanisms, and the
immune system. The pain relief reported by patients occurs
as a result of all these phenomena.
The Italian Society of Mesotherapy considers that the
intradermal injection of drugs is eﬀective and well tolerated10 Evidence-Based Complementary and Alternative Medicine
if administered according to approved techniques and when
administered after a complete clinical workup from which
there is a clear rationale for local treatment. We believe
that this method provides potential beneﬁts in terms of
clinical eﬀectiveness and cost savings in the management of
musculoskeletal pain. Many studies have been conducted in
theopen,andfewrandomizedcontrolledtrialshavealimited
number of subjects, it should be pointed out however that
more large-scale and randomized clinical trials are required
to conﬁrm its eﬃcacy and tolerability in general, and in
particular we have identiﬁed two important areas for further
reach: ﬁrst to conﬁrm the eﬃcacy of intradermal NSAIDs
in localized pain to reduce the risk of the known systemic
eﬀectsofthisclassofdrugsandsecondtheuseofintradermal
opioids in order to improve our understanding of how to
extendtheeﬀectivenessoftheseanalgesicsinmusculoskeletal
painful conditions.
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